BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. 1994

L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Centro Richerche per la Manipolazione dei Costituenti Ematici, Catholic University, Rome, Italy.

We tested in vitro the effect of recombinant human erythropoietin (rhEPO) plus recombinant human G-CSF (rhG-CSF) on purified human CD34+ haemopoietic progenitors (HP) and in vivo in patients who had undergone anti-cancer chemotherapy for advanced ovarian cancer. In this preliminary experience we found that, in vitro, rhEPO potentiates the effect of rhG-CSF on HP growth and differentiation toward the granulocyte-macrophage lineage. rhEPO plus rhG-CSF produced in vitro a proliferative stimulus of HP which represents 26% of the maximum stimulation obtained using IL-1, IL-3, IL-6, G-CSF, GM-CSF and stem cell factor in combination. In the patients treated with rhEPO plus rhG-CSF after chemotherapy, we observed a favourable trend for platelet and neutrophil recoveries compared with a control group treated with rhG-CSF alone and a significantly higher haematocrit nadir was observed in the rhEPO plus rhG-CSF series. In the patients treated with rhEPO plus rhG-CSF we observed a significant increase of circulating colony-forming unit granulocyte-macrophage (CFU-GM) and burst forming unit-erythroid (BFU-e) compared with the rhG-CSF series. Our results, in vitro and in vivo, encourage the in vivo use of rhEPO plus rhG-CSF to improve blood cell recoveries of patients who have undergone conventional or high-dose chemotherapy. Moreover, rhEPO plus rhG-CSF was demonstrated to be a good HP mobilising treatment for blood stem cell collection after chemotherapy.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females

Related Publications

L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
In vitro and in vivo effects of recombinant human erythropoietin on human hemopoietic progenitor cells.
January 1988, Contributions to nephrology,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
In vivo effects of recombinant human erythropoietin on circulating human hemopoietic progenitor cells.
June 1989, Experimental hematology,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Recombinant human erythropoietin and hematopoietic progenitor cells in vivo.
June 1989, Blood,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Effects of erythropoietin on mobilisation of haemopoietic progenitor cells.
July 1994, Bone marrow transplantation,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Differential effects of recombinant human interleukin-13 on the in vitro growth of human haemopoietic progenitor cells.
August 1995, British journal of haematology,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro.
March 1988, Klinische Wochenschrift,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
In vitro chronopharmacology of recombinant mouse IL-3, mouse GM-CSF, and human G-CSF on murine myeloid progenitor cells.
April 1995, Experimental hematology,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Effects of recombinant human G-CSF and GM-CSF on primary human leukemic cells.
September 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
Action of interleukin-3, G-CSF, and GM-CSF on highly enriched human hematopoietic progenitor cells: synergistic interaction of GM-CSF plus G-CSF.
July 1989, Blood,
L Pierelli, and G Menichella, and G Scambia, and L Teofili, and S Iovino, and R Serafini, and P Benedetti Panici, and G Salerno, and C Rumi, and G Zini
[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells].
January 1990, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
Copied contents to your clipboard!